Cargando…

IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens

RV144 correlates of risk analysis showed that IgG antibodies to gp70V1V2 scaffolds inversely correlated with risk of HIV acquisition. We investigated IgG antibody responses in RV135 and RV132, two ALVAC-HIV prime-boost vaccine trials conducted in Thailand prior to RV144. Both trials used ALVAC-HIV (...

Descripción completa

Detalles Bibliográficos
Autores principales: Karasavvas, Nicos, Karnasuta, Chitraporn, Savadsuk, Hathairat, Madnote, Sirinan, Inthawong, Dutsadee, Chantakulkij, Somsak, Rittiroongrad, Surawach, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Thongcharoen, Prasert, Siriyanon, Vinai, Andrews, Charla A., Barnett, Susan W., Tartaglia, James, Sinangil, Faruk, Francis, Donald P., Robb, Merlin L., Michael, Nelson L., Ngauy, Viseth, de Souza, Mark S., Paris, Robert M., Excler, Jean-Louis, Kim, Jerome H., O'Connell, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651018/
https://www.ncbi.nlm.nih.gov/pubmed/26234467
http://dx.doi.org/10.1089/aid.2015.0034
_version_ 1782401598542053376
author Karasavvas, Nicos
Karnasuta, Chitraporn
Savadsuk, Hathairat
Madnote, Sirinan
Inthawong, Dutsadee
Chantakulkij, Somsak
Rittiroongrad, Surawach
Nitayaphan, Sorachai
Pitisuttithum, Punnee
Thongcharoen, Prasert
Siriyanon, Vinai
Andrews, Charla A.
Barnett, Susan W.
Tartaglia, James
Sinangil, Faruk
Francis, Donald P.
Robb, Merlin L.
Michael, Nelson L.
Ngauy, Viseth
de Souza, Mark S.
Paris, Robert M.
Excler, Jean-Louis
Kim, Jerome H.
O'Connell, Robert J.
author_facet Karasavvas, Nicos
Karnasuta, Chitraporn
Savadsuk, Hathairat
Madnote, Sirinan
Inthawong, Dutsadee
Chantakulkij, Somsak
Rittiroongrad, Surawach
Nitayaphan, Sorachai
Pitisuttithum, Punnee
Thongcharoen, Prasert
Siriyanon, Vinai
Andrews, Charla A.
Barnett, Susan W.
Tartaglia, James
Sinangil, Faruk
Francis, Donald P.
Robb, Merlin L.
Michael, Nelson L.
Ngauy, Viseth
de Souza, Mark S.
Paris, Robert M.
Excler, Jean-Louis
Kim, Jerome H.
O'Connell, Robert J.
author_sort Karasavvas, Nicos
collection PubMed
description RV144 correlates of risk analysis showed that IgG antibodies to gp70V1V2 scaffolds inversely correlated with risk of HIV acquisition. We investigated IgG antibody responses in RV135 and RV132, two ALVAC-HIV prime-boost vaccine trials conducted in Thailand prior to RV144. Both trials used ALVAC-HIV (vCP1521) at 0, 1, 3, and 6 months and HIV-1 gp120MNgD and gp120A244gD in alum (RV135) or gp120SF2 and gp120CM235 in MF59 (RV132) at 3 and 6 months. We assessed ELISA binding antibodies to the envelope proteins (Env) 92TH023, A244gD and MNgD, cyclicV2, and gp70V1V2 CaseA2 (subtype B) and 92TH023 (subtype CRF01_AE), and Env-specific IgG1 and IgG3. Antibody responses to gp120 A244gD, MNgD, and gp70V1V2 92TH023 scaffold were significantly higher in RV135 than in RV132. Antibodies to gp70V1V2 CaseA2 were detected only in RV135 vaccine recipients and IgG1 and IgG3 antibody responses to A244gD were significantly higher in RV135. IgG binding to gp70V1V2 CaseA2 and CRF01_AE scaffolds was higher with the AIDSVAX(®)B/E boost but both trials showed similar rates of antibody decline post-vaccination. MF59 did not result in higher IgG antibody responses compared to alum with the antigens tested. However, notable differences in the structure of the recombinant proteins and dosage used for immunizations may have contributed to the magnitude and specificity of IgG induced by the two trials.
format Online
Article
Text
id pubmed-4651018
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Mary Ann Liebert, Inc.
record_format MEDLINE/PubMed
spelling pubmed-46510182015-12-02 IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens Karasavvas, Nicos Karnasuta, Chitraporn Savadsuk, Hathairat Madnote, Sirinan Inthawong, Dutsadee Chantakulkij, Somsak Rittiroongrad, Surawach Nitayaphan, Sorachai Pitisuttithum, Punnee Thongcharoen, Prasert Siriyanon, Vinai Andrews, Charla A. Barnett, Susan W. Tartaglia, James Sinangil, Faruk Francis, Donald P. Robb, Merlin L. Michael, Nelson L. Ngauy, Viseth de Souza, Mark S. Paris, Robert M. Excler, Jean-Louis Kim, Jerome H. O'Connell, Robert J. AIDS Res Hum Retroviruses Vaccines RV144 correlates of risk analysis showed that IgG antibodies to gp70V1V2 scaffolds inversely correlated with risk of HIV acquisition. We investigated IgG antibody responses in RV135 and RV132, two ALVAC-HIV prime-boost vaccine trials conducted in Thailand prior to RV144. Both trials used ALVAC-HIV (vCP1521) at 0, 1, 3, and 6 months and HIV-1 gp120MNgD and gp120A244gD in alum (RV135) or gp120SF2 and gp120CM235 in MF59 (RV132) at 3 and 6 months. We assessed ELISA binding antibodies to the envelope proteins (Env) 92TH023, A244gD and MNgD, cyclicV2, and gp70V1V2 CaseA2 (subtype B) and 92TH023 (subtype CRF01_AE), and Env-specific IgG1 and IgG3. Antibody responses to gp120 A244gD, MNgD, and gp70V1V2 92TH023 scaffold were significantly higher in RV135 than in RV132. Antibodies to gp70V1V2 CaseA2 were detected only in RV135 vaccine recipients and IgG1 and IgG3 antibody responses to A244gD were significantly higher in RV135. IgG binding to gp70V1V2 CaseA2 and CRF01_AE scaffolds was higher with the AIDSVAX(®)B/E boost but both trials showed similar rates of antibody decline post-vaccination. MF59 did not result in higher IgG antibody responses compared to alum with the antigens tested. However, notable differences in the structure of the recombinant proteins and dosage used for immunizations may have contributed to the magnitude and specificity of IgG induced by the two trials. Mary Ann Liebert, Inc. 2015-11-01 /pmc/articles/PMC4651018/ /pubmed/26234467 http://dx.doi.org/10.1089/aid.2015.0034 Text en © Nicos Karasavvas et al. 2015; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Vaccines
Karasavvas, Nicos
Karnasuta, Chitraporn
Savadsuk, Hathairat
Madnote, Sirinan
Inthawong, Dutsadee
Chantakulkij, Somsak
Rittiroongrad, Surawach
Nitayaphan, Sorachai
Pitisuttithum, Punnee
Thongcharoen, Prasert
Siriyanon, Vinai
Andrews, Charla A.
Barnett, Susan W.
Tartaglia, James
Sinangil, Faruk
Francis, Donald P.
Robb, Merlin L.
Michael, Nelson L.
Ngauy, Viseth
de Souza, Mark S.
Paris, Robert M.
Excler, Jean-Louis
Kim, Jerome H.
O'Connell, Robert J.
IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens
title IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens
title_full IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens
title_fullStr IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens
title_full_unstemmed IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens
title_short IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens
title_sort igg antibody responses to recombinant gp120 proteins, gp70v1/v2 scaffolds, and a cyclicv2 peptide in thai phase i/ii vaccine trials using different vaccine regimens
topic Vaccines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651018/
https://www.ncbi.nlm.nih.gov/pubmed/26234467
http://dx.doi.org/10.1089/aid.2015.0034
work_keys_str_mv AT karasavvasnicos iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT karnasutachitraporn iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT savadsukhathairat iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT madnotesirinan iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT inthawongdutsadee iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT chantakulkijsomsak iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT rittiroongradsurawach iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT nitayaphansorachai iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT pitisuttithumpunnee iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT thongcharoenprasert iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT siriyanonvinai iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT andrewscharlaa iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT barnettsusanw iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT tartagliajames iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT sinangilfaruk iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT francisdonaldp iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT robbmerlinl iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT michaelnelsonl iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT ngauyviseth iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT desouzamarks iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT parisrobertm iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT exclerjeanlouis iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT kimjeromeh iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens
AT oconnellrobertj iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens